Zanidip 20mg 98 tablets — Made in Italy — Free Delivery

Mild or moderate essential hypertension.

Hypersensitivity to lercanidipine or to any component of the preparation.

Obstruction of the outflow tract of the left ventricle.

Untreated congestive heart failure.

Unstable angina or recent (within 1 month) myocardial infarction.

Severe liver failure.

Severe renal failure (creatinine clearance <30 ml/min), including patients on hemodialysis.

Simultaneous use with potent inhibitors of CYP3A4, cyclosporine, grapefruit or grapefruit juice.

active ingredient: 1 tablet contains 10 mg lercanidipine hydrochloride (equivalent to 9.4 mg lercanidipine) or 20 mg lercanidipine hydrochloride (equivalent to 18.8 mg lercanidipine)

excipients: lactose, microcrystalline cellulose, sodium starch (type A), povidone K30, magnesium stearate

shell for a tablet with a dosage of 10 mg Opadry OY-SR-6497 (hypromellose, talc, titanium dioxide (E 171), macrogol 6000, iron oxide yellow (E172))

shell for a tablet with a dosage of 20 mg Opadry 02F25077 (hypromellose, talc, titanium dioxide (E 171), macrogol 6000, iron oxide red (E172)).

The recommended dose is 10 mg orally once a day at least 15 minutes before a meal. Depending on the patient's individual response to treatment, the dose may be increased to 20 mg.

Dose titration should be gradual, since the maximum antihypertensive effect develops within 2 weeks of treatment.

Patients whose blood pressure will be adequately controlled on monotherapy with antihypertensive preparations may be offered to add Zanidip® to regimens with b-blockers (atenolol), diuretics (hydrochlorothiazide) or ACE inhibitors (captopril or enalapril).

Since the dose-response curve has a plateau between doses of 20-30 mg, it is unlikely that the effectiveness of the preparation will increase with a high dose, while the risk of side effects may increase.

According to pharmacokinetic and clinical studies, Zanidip® can be used in elderly patients without special dose adjustments, but treatment of elderly patients should be started under supervision.

Patients with renal or hepatic insufficiency.

In patients with mild to moderate renal or hepatic insufficiency, treatment with Zanidip® should be initiated under supervision. The recommended dose of 10 mg is generally well tolerated by patients in these subgroups, but increasing the dose to 20 mg requires caution.

In patients with hepatic insufficiency, an increase in the antihypertensive effect of the preparation is possible, which requires dose adjustment.

Lercanidipine is contraindicated in patients with severe hepatic dysfunction or severe renal dysfunction (creatinine clearance <30 ml/min), including patients on hemodialysis.

Before using the preparation, it is necessary to take into account that:

apply the preparation preferably in the morning, at least 15 minutes before breakfast;

this medicine should not be taken with grapefruit juice.

Children.

The safety and efficacy of the preparation in children under 18 years of age have not been studied, data on the use of children are not available.